You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSaquinavir
Accession NumberDB01232  (APRD00623)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. [PubChem]
Structure
Thumb
Synonyms
Saquinavir Mesylate
SQV
External Identifiers
  • RO 31-8959/000
  • SCH-52852
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fortovase Rochecapsule200 mgoralHoffmann La Roche Limited1998-11-262007-03-06Canada
InviraseCapsule, hard200 mgOral useRoche Registration Limited1996-10-04Not applicableEu
Invirasetablet, film coated500 mg/1oralGenentech, Inc.2004-12-17Not applicableUs
InviraseFilm-Coated tablet500 mgOral useRoche Registration Limited1996-10-04Not applicableEu
Invirasecapsule200 mg/1oralGenentech, Inc.1995-12-06Not applicableUs
Invirasetablet500 mgoralHoffmann La Roche Limited2006-04-10Not applicableCanada
Invirasecapsule200 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Invirasetablet, film coated500 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Invirase - Cap 200mgcapsule200 mgoralHoffmann La Roche Limited1996-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FortovaseNot Available
ROCNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIL3JE09KZ2F
CAS number127779-20-8
WeightAverage: 670.8408
Monoisotopic: 670.38426874
Chemical FormulaC38H50N6O5
InChI KeyQWAXKHKRTORLEM-UGJKXSETSA-N
InChI
InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
IUPAC Name
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butyl-C-hydroxycarbonimidoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediimidic acid
SMILES
[H][C@@](O)(CN1C[C@@]2([H])CCCC[C@@]2([H])C[C@@]1([H])C(O)=NC(C)(C)C)[C@]([H])(CC1=CC=CC=C1)N=C(O)[C@]([H])(CC(O)=N)NC(=O)C1=NC2=CC=CC=C2C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids and derivatives
Alternative Parents
Substituents
  • Quinoline-2-carboxamide
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid amide
  • Phenylbutylamine
  • Quinoline
  • Amphetamine or derivatives
  • Pyridine carboxylic acid or derivatives
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • Aralkylamine
  • Fatty acyl
  • Benzenoid
  • Pyridine
  • Piperidine
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
PharmacodynamicsSaquinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Saquinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism of actionSaquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Related Articles
AbsorptionAbsolute bioavailability averages 4%
Volume of distribution
  • 700 L
Protein binding98%
Metabolism

Hepatic

SubstrateEnzymesProduct
Saquinavir
M2 di-hydroxylated metaboliteDetails
Route of eliminationIn vitro studies using human liver microsomes have shown that the metabolism of saquinavir is cytochrome P450 mediated with the specific isoenzyme, CYP3A4, responsible for more than 90% of the hepatic metabolism. Only 1% of saquinavir is excreted in the urine, so the impact of renal impairment on saquinavir elimination should be minimal.
Half lifeNot Available
Clearance
  • 1.14 L/h/kg [Healthy volunteers receiving IV doses of 6, 36, and 72 mg]
ToxicityProbably experience pain in the throat
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7774
Blood Brain Barrier-0.9949
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.9048
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.5195
Renal organic cation transporterNon-inhibitor0.8612
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7406
CYP450 1A2 substrateNon-inhibitor0.8729
CYP450 2C9 inhibitorNon-inhibitor0.7442
CYP450 2D6 inhibitorNon-inhibitor0.8536
CYP450 2C19 inhibitorNon-inhibitor0.7124
CYP450 3A4 inhibitorInhibitor0.5219
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9053
Ames testNon AMES toxic0.8489
CarcinogenicityNon-carcinogens0.865
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6007 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9687
hERG inhibition (predictor II)Inhibitor0.8153
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral200 mg/1
Capsule, hardOral use200 mg
Film-coated tabletOral use500 mg
Tabletoral500 mg
Tablet, film coatedoral500 mg/1
Capsuleoral200 mg
Prices
Unit descriptionCostUnit
Invirase 500 mg tablet8.72USD tablet
Invirase 200 mg capsule3.87USD capsule
Fortovase 200 mg capsule1.46USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2030433 No1997-10-212010-11-21Canada
CA2224125 No2004-09-282016-06-04Canada
US5196438 No1993-11-192010-11-19Us
US6008228 Yes1995-12-062015-12-06Us
US6352717 Yes2000-05-162020-05-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point349.84 °CNot Available
water solubilityInsolubleNot Available
logP3.8Not Available
Caco2 permeability-6.26ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00765 mg/mLALOGPS
logP3.96ALOGPS
logP2.58ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)5.11ChemAxon
pKa (Strongest Basic)8.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area174.72 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity198.65 m3·mol-1ChemAxon
Polarizability74.25 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US5196438
General References
  1. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L: Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol. 2001 Jul;185(1):178-81. [PubMed:11483925 ]
External Links
ATC CodesJ05AE01
AHFS Codes
  • 08:18.08.08
PDB Entries
FDA labelDownload (362 KB)
MSDSDownload (15.8 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Saquinavir.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Saquinavir.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Saquinavir.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Saquinavir.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Saquinavir.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Saquinavir.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Saquinavir.
AcetaminophenThe serum concentration of Saquinavir can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Saquinavir.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Saquinavir.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Saquinavir.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Saquinavir.
AfatinibThe serum concentration of Saquinavir can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Saquinavir.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Saquinavir.
AlbendazoleThe serum concentration of Saquinavir can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Saquinavir.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Saquinavir.
AlectinibThe serum concentration of Saquinavir can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Saquinavir.
AlfentanilThe serum concentration of Saquinavir can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Saquinavir.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Saquinavir.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Saquinavir.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Saquinavir.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Saquinavir.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Saquinavir.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Saquinavir.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Saquinavir.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Saquinavir.
AmantadineAmantadine may increase the QTc-prolonging activities of Saquinavir.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Saquinavir.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Saquinavir.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Saquinavir.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Saquinavir.
Aminohippuric acidThe serum concentration of Saquinavir can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Saquinavir.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Saquinavir.
AmiodaroneSaquinavir may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe serum concentration of Saquinavir can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Saquinavir.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Saquinavir.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Saquinavir.
AmlodipineThe serum concentration of Saquinavir can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Saquinavir.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Saquinavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Saquinavir.
AmprenavirThe serum concentration of Saquinavir can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Saquinavir can be increased when it is combined with Amsacrine.
AnagrelideSaquinavir may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Saquinavir.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Saquinavir.
ApomorphineApomorphine may increase the QTc-prolonging activities of Saquinavir.
ApremilastThe metabolism of Apremilast can be decreased when combined with Saquinavir.
AprepitantThe serum concentration of Saquinavir can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Saquinavir.
ArformoterolArformoterol may increase the QTc-prolonging activities of Saquinavir.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Saquinavir.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Saquinavir.
Arsenic trioxideSaquinavir may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherSaquinavir may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Saquinavir can be decreased when combined with Artemether.
AsenapineThe serum concentration of Saquinavir can be increased when it is combined with Asenapine.
AsenapineSaquinavir may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Saquinavir.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Saquinavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Saquinavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Saquinavir.
AtenololThe serum concentration of Saquinavir can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Saquinavir.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Saquinavir.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Saquinavir.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Saquinavir.
AzelastineThe metabolism of Azelastine can be decreased when combined with Saquinavir.
AzelastineThe serum concentration of Saquinavir can be increased when it is combined with Azelastine.
AzithromycinSaquinavir may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Saquinavir can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Saquinavir.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Saquinavir.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Saquinavir.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Saquinavir.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Saquinavir.
BenzocaineThe serum concentration of Saquinavir can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Saquinavir.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Saquinavir.
BepridilBepridil may increase the arrhythmogenic activities of Saquinavir.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Saquinavir.
BetaxololThe metabolism of Saquinavir can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Saquinavir can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Saquinavir.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Saquinavir.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Saquinavir.
BiperidenThe serum concentration of Saquinavir can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Saquinavir.
BoceprevirThe serum concentration of Saquinavir can be decreased when it is combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Saquinavir.
BortezomibBortezomib may increase the QTc-prolonging activities of Saquinavir.
BosentanThe serum concentration of Saquinavir can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Saquinavir.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Saquinavir.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Saquinavir.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Saquinavir.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Saquinavir.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Saquinavir.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Saquinavir.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Saquinavir.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Saquinavir.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Saquinavir.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Saquinavir.
BuprenorphineThe serum concentration of Saquinavir can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Saquinavir.
BuserelinBuserelin may increase the QTc-prolonging activities of Saquinavir.
BuspironeThe metabolism of Buspirone can be decreased when combined with Saquinavir.
BuspironeThe serum concentration of Saquinavir can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Saquinavir.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Saquinavir.
CabazitaxelThe serum concentration of Saquinavir can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Saquinavir.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Saquinavir.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Saquinavir.
CaffeineThe serum concentration of Saquinavir can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Saquinavir.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Saquinavir.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Saquinavir.
CanagliflozinThe serum concentration of Saquinavir can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Saquinavir can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Saquinavir can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Saquinavir.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Saquinavir.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Saquinavir.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Saquinavir.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Saquinavir.
CarvedilolThe serum concentration of Saquinavir can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Saquinavir can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Saquinavir.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Saquinavir.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Saquinavir.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Saquinavir.
CeritinibThe serum concentration of Saquinavir can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Saquinavir.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Saquinavir.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Saquinavir.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Saquinavir.
ChloroquineSaquinavir may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Saquinavir can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Saquinavir.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Saquinavir.
ChlorpromazineThe serum concentration of Saquinavir can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Saquinavir.
ChlorpropamideThe serum concentration of Saquinavir can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Saquinavir can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Saquinavir.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Saquinavir.
CholesterolThe serum concentration of Saquinavir can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Saquinavir can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Saquinavir.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Saquinavir.
CilazaprilThe serum concentration of Saquinavir can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Saquinavir.
CimetidineThe serum concentration of Saquinavir can be increased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Saquinavir.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Saquinavir.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Saquinavir.
CiprofloxacinThe serum concentration of Saquinavir can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Saquinavir.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Saquinavir.
CitalopramSaquinavir may increase the QTc-prolonging activities of Citalopram.
CitalopramThe serum concentration of Saquinavir can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Saquinavir.
ClarithromycinThe serum concentration of Saquinavir can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Saquinavir can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Saquinavir.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Saquinavir.
ClobazamThe metabolism of Saquinavir can be decreased when combined with Clobazam.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Saquinavir.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Saquinavir.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Saquinavir.
ClofazimineThe serum concentration of Saquinavir can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Saquinavir.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Saquinavir.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Saquinavir.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Saquinavir.
ClomipramineClomipramine may increase the QTc-prolonging activities of Saquinavir.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Saquinavir.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Saquinavir.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Saquinavir.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Saquinavir.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Saquinavir.
ClotrimazoleThe metabolism of Saquinavir can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Saquinavir.
ClozapineThe metabolism of Saquinavir can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Saquinavir can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Saquinavir.
CocaineThe metabolism of Cocaine can be decreased when combined with Saquinavir.
CodeineThe metabolism of Codeine can be decreased when combined with Saquinavir.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Saquinavir.
ColchicineThe serum concentration of Saquinavir can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Saquinavir can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Saquinavir can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Saquinavir.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Saquinavir.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Saquinavir.
CrizotinibThe metabolism of Saquinavir can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Saquinavir.
CyclophosphamideThe risk or severity of adverse effects can be increased when Saquinavir is combined with Cyclophosphamide.
CyclophosphamideThe serum concentration of Saquinavir can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Saquinavir can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Saquinavir.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Saquinavir.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Saquinavir.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Saquinavir.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Saquinavir.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Saquinavir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Saquinavir.
DactinomycinThe serum concentration of Saquinavir can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Saquinavir.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Saquinavir.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Saquinavir.
DapsoneThe metabolism of Dapsone can be decreased when combined with Saquinavir.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Saquinavir.
DarunavirThe serum concentration of Saquinavir can be increased when it is combined with Darunavir.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Saquinavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Saquinavir.
DasatinibThe serum concentration of Saquinavir can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Saquinavir.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Saquinavir.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Saquinavir.
DeferasiroxThe serum concentration of Saquinavir can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Saquinavir.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Saquinavir.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Saquinavir.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Saquinavir.
DelavirdineThe metabolism of Saquinavir can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Saquinavir.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Saquinavir.
DesipramineDesipramine may increase the QTc-prolonging activities of Saquinavir.
DesloratadineThe serum concentration of Saquinavir can be increased when it is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Saquinavir.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Saquinavir.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Saquinavir.
DexamethasoneThe serum concentration of Saquinavir can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Saquinavir.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Saquinavir.
DextromethorphanThe serum concentration of Saquinavir can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Saquinavir.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Saquinavir.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Saquinavir.
DiclofenacThe serum concentration of Saquinavir can be increased when it is combined with Diclofenac.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Saquinavir.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Saquinavir.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Saquinavir.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Saquinavir.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Saquinavir.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Saquinavir.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Saquinavir.
DigoxinThe serum concentration of Saquinavir can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Saquinavir.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Saquinavir.
DihydroergotamineThe metabolism of Saquinavir can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Saquinavir.
DiltiazemThe metabolism of Saquinavir can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Saquinavir.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Saquinavir.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Saquinavir.
DipyridamoleThe serum concentration of Saquinavir can be increased when it is combined with Dipyridamole.
DisopyramideSaquinavir may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Saquinavir.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Saquinavir.
DofetilideSaquinavir may increase the arrhythmogenic activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Saquinavir.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Saquinavir.
DonepezilThe metabolism of Donepezil can be decreased when combined with Saquinavir.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Saquinavir.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Saquinavir.
DoxazosinThe serum concentration of Saquinavir can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Saquinavir can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Saquinavir.
DoxycyclineThe metabolism of Saquinavir can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Saquinavir.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Saquinavir.
DronedaroneThe metabolism of Saquinavir can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Saquinavir.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Saquinavir.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Saquinavir.
DuloxetineThe metabolism of Saquinavir can be decreased when combined with Duloxetine.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Saquinavir.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Saquinavir.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Saquinavir.
EfavirenzThe risk or severity of adverse effects can be increased when Saquinavir is combined with Efavirenz.
EfavirenzThe serum concentration of Saquinavir can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Saquinavir can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Saquinavir.
EliglustatSaquinavir may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Saquinavir can be decreased when combined with Eliglustat.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Saquinavir.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Saquinavir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Saquinavir.
EnalaprilThe serum concentration of Saquinavir can be increased when it is combined with Enalapril.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Saquinavir.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Saquinavir.
EpinastineThe serum concentration of Saquinavir can be increased when it is combined with Epinastine.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Saquinavir.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Saquinavir.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Saquinavir.
EquilinThe serum concentration of Equilin can be increased when it is combined with Saquinavir.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Saquinavir.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saquinavir.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Saquinavir.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Saquinavir.
EribulinEribulin may increase the QTc-prolonging activities of Saquinavir.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Saquinavir.
ErythromycinThe metabolism of Saquinavir can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Saquinavir.
EscitalopramSaquinavir may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Saquinavir can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Saquinavir.
EsomeprazoleThe serum concentration of Saquinavir can be increased when it is combined with Esomeprazole.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Saquinavir.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Saquinavir.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Saquinavir.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Saquinavir.
EstramustineThe metabolism of Estramustine can be decreased when combined with Saquinavir.
EstramustineThe serum concentration of Saquinavir can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Saquinavir.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Saquinavir.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Saquinavir.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Saquinavir.
EthanolThe metabolism of Ethanol can be decreased when combined with Saquinavir.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Saquinavir.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Saquinavir.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Saquinavir.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Saquinavir.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Saquinavir.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Saquinavir.
EtoposideThe serum concentration of Saquinavir can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Saquinavir.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Saquinavir.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Saquinavir.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Saquinavir.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Saquinavir.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Saquinavir.
EzogabineEzogabine may increase the QTc-prolonging activities of Saquinavir.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Saquinavir.
FamotidineThe serum concentration of Saquinavir can be increased when it is combined with Famotidine.
FelbamateFelbamate may increase the QTc-prolonging activities of Saquinavir.
FelbamateThe metabolism of Felbamate can be decreased when combined with Saquinavir.
FelodipineThe metabolism of Felodipine can be decreased when combined with Saquinavir.
FelodipineThe serum concentration of Saquinavir can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Saquinavir.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Saquinavir.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Saquinavir.
FexofenadineThe serum concentration of Saquinavir can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Saquinavir.
FidaxomicinThe serum concentration of Saquinavir can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be decreased when combined with Saquinavir.
FingolimodFingolimod may increase the QTc-prolonging activities of Saquinavir.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Saquinavir.
FlecainideSaquinavir may increase the arrhythmogenic activities of Flecainide.
FlecainideFlecainide may increase the QTc-prolonging activities of Saquinavir.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Saquinavir.
FluconazoleFluconazole may increase the QTc-prolonging activities of Saquinavir.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Saquinavir.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Saquinavir.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Saquinavir.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Saquinavir.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Saquinavir.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Saquinavir.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Saquinavir.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Saquinavir.
FluoxetineSaquinavir may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe serum concentration of Saquinavir can be increased when it is combined with Fluoxetine.
FlupentixolSaquinavir may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Saquinavir can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Saquinavir can be increased when it is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Saquinavir.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Saquinavir.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Saquinavir.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Saquinavir.
FlutamideThe metabolism of Flutamide can be decreased when combined with Saquinavir.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Saquinavir.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Saquinavir.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Saquinavir.
FluvoxamineThe metabolism of Saquinavir can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Saquinavir.
FosamprenavirThe metabolism of Saquinavir can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Saquinavir can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Saquinavir.
FosphenytoinThe metabolism of Saquinavir can be increased when combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Saquinavir.
Fusidic AcidThe serum concentration of Saquinavir can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Saquinavir.
GalantamineGalantamine may increase the QTc-prolonging activities of Saquinavir.
GalantamineThe metabolism of Galantamine can be decreased when combined with Saquinavir.
GarlicThe serum concentration of Saquinavir can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Saquinavir.
GefitinibThe serum concentration of Saquinavir can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Saquinavir.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Saquinavir.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Saquinavir.
GenisteinThe serum concentration of Saquinavir can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Saquinavir.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Saquinavir.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Saquinavir.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Saquinavir.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Saquinavir.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Saquinavir.
GlyburideThe serum concentration of Saquinavir can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Saquinavir can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Saquinavir.
Gramicidin DThe serum concentration of Saquinavir can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Saquinavir.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Saquinavir.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Saquinavir.
GrepafloxacinThe serum concentration of Saquinavir can be increased when it is combined with Grepafloxacin.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Saquinavir.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Saquinavir.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Saquinavir.
HaloperidolThe serum concentration of Saquinavir can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Saquinavir.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Saquinavir.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Saquinavir.
HistrelinHistrelin may increase the QTc-prolonging activities of Saquinavir.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Saquinavir.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Saquinavir.
HydrocortisoneThe serum concentration of Saquinavir can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Saquinavir.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Saquinavir.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Saquinavir.
IbandronateIbandronate may increase the QTc-prolonging activities of Saquinavir.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Saquinavir.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Saquinavir.
IbutilideSaquinavir may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Saquinavir can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Saquinavir resulting in a loss in efficacy.
IloperidoneSaquinavir may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Saquinavir.
ImatinibThe metabolism of Saquinavir can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Saquinavir.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Saquinavir.
ImipramineImipramine may increase the QTc-prolonging activities of Saquinavir.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Saquinavir.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Saquinavir.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Saquinavir.
IndapamideIndapamide may increase the QTc-prolonging activities of Saquinavir.
IndapamideThe metabolism of Indapamide can be decreased when combined with Saquinavir.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Saquinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Saquinavir.
IndomethacinThe serum concentration of Saquinavir can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Saquinavir.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Saquinavir.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Saquinavir.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Saquinavir.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Saquinavir.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Saquinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Saquinavir.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Saquinavir.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Saquinavir.
IsavuconazoniumThe metabolism of Saquinavir can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Saquinavir.
IsoniazidThe metabolism of Saquinavir can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Saquinavir.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Saquinavir.
IsradipineIsradipine may increase the QTc-prolonging activities of Saquinavir.
IsradipineThe metabolism of Isradipine can be decreased when combined with Saquinavir.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Saquinavir.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Saquinavir.
IvabradineIvabradine may increase the QTc-prolonging activities of Saquinavir.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Saquinavir.
IvacaftorThe serum concentration of Saquinavir can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Saquinavir.
IvermectinThe serum concentration of Saquinavir can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Saquinavir.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Saquinavir.
KetamineThe metabolism of Ketamine can be decreased when combined with Saquinavir.
KetamineThe serum concentration of Saquinavir can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Saquinavir.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Saquinavir.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Saquinavir.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Saquinavir.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Saquinavir.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Saquinavir.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Saquinavir.
LansoprazoleThe serum concentration of Saquinavir can be increased when it is combined with Lansoprazole.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Saquinavir.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Saquinavir.
LapatinibLapatinib may increase the QTc-prolonging activities of Saquinavir.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Saquinavir.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Saquinavir.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Saquinavir.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Saquinavir.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Saquinavir.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Saquinavir.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Saquinavir.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Saquinavir.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Saquinavir.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Saquinavir.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Saquinavir.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Saquinavir.
LevofloxacinThe serum concentration of Saquinavir can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Saquinavir.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Saquinavir.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Saquinavir.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Saquinavir.
LevothyroxineThe serum concentration of Saquinavir can be decreased when it is combined with Levothyroxine.
LidocaineSaquinavir may increase the arrhythmogenic activities of Lidocaine.
LidocaineThe serum concentration of Saquinavir can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Saquinavir.
LiothyronineThe serum concentration of Saquinavir can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Saquinavir can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Saquinavir.
LisinoprilThe serum concentration of Saquinavir can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Saquinavir.
LithiumLithium may increase the QTc-prolonging activities of Saquinavir.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Saquinavir.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Saquinavir.
LoperamideThe serum concentration of Saquinavir can be increased when it is combined with Loperamide.
LopinavirSaquinavir may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe serum concentration of Saquinavir can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Saquinavir.
LoratadineThe serum concentration of Saquinavir can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Saquinavir.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Saquinavir.
LosartanThe serum concentration of Saquinavir can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Saquinavir.
LovastatinThe metabolism of Saquinavir can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Saquinavir can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Saquinavir can be decreased when it is combined with Lumacaftor.
LumefantrineSaquinavir may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Saquinavir can be decreased when combined with Lumefantrine.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Saquinavir.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Saquinavir.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Saquinavir.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Saquinavir.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Saquinavir.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Saquinavir.
MebendazoleThe serum concentration of Saquinavir can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Saquinavir.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Saquinavir.
MefloquineMefloquine may increase the QTc-prolonging activities of Saquinavir.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Saquinavir.
Megestrol acetateThe serum concentration of Saquinavir can be increased when it is combined with Megestrol acetate.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Saquinavir.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Saquinavir.
MeprobamateThe serum concentration of Saquinavir can be increased when it is combined with Meprobamate.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.
MethadoneSaquinavir may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Saquinavir can be increased when it is combined with Methadone.
MethanthelineThe serum concentration of Saquinavir can be increased when it is combined with Methantheline.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Saquinavir.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Saquinavir.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Saquinavir.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Saquinavir.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Saquinavir.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Saquinavir.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Saquinavir.
MetiamideThe serum concentration of Saquinavir can be increased when it is combined with Metiamide.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Saquinavir.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Saquinavir.
MetoprololThe serum concentration of Saquinavir can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Saquinavir.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Saquinavir.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Saquinavir.
MianserinThe metabolism of Mianserin can be decreased when combined with Saquinavir.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Saquinavir.
MibefradilThe serum concentration of Saquinavir can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Saquinavir.
MiconazoleThe serum concentration of Saquinavir can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Saquinavir.
MidazolamThe serum concentration of Saquinavir can be decreased when it is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Saquinavir.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Saquinavir.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Saquinavir.
MirabegronMirabegron may increase the QTc-prolonging activities of Saquinavir.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Saquinavir.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Saquinavir.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Saquinavir.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Saquinavir.
MitomycinThe serum concentration of Saquinavir can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Saquinavir can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Saquinavir.
ModafinilThe serum concentration of Saquinavir can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Saquinavir.
MoexiprilMoexipril may increase the QTc-prolonging activities of Saquinavir.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Saquinavir.
MontelukastThe metabolism of Montelukast can be decreased when combined with Saquinavir.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Saquinavir.
MorphineThe serum concentration of Saquinavir can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Saquinavir.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Saquinavir.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Saquinavir.
NafcillinThe serum concentration of Saquinavir can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Saquinavir.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Saquinavir.
NaltrexoneThe serum concentration of Saquinavir can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Saquinavir can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Saquinavir.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Saquinavir.
NefazodoneThe serum concentration of Saquinavir can be decreased when it is combined with Nefazodone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Saquinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Saquinavir.
NeostigmineThe serum concentration of Saquinavir can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Saquinavir can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Saquinavir can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Saquinavir.
NicardipineNicardipine may increase the QTc-prolonging activities of Saquinavir.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Saquinavir.
NicotineThe metabolism of Nicotine can be decreased when combined with Saquinavir.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Saquinavir.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Saquinavir.
NilotinibThe metabolism of Saquinavir can be decreased when combined with Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Saquinavir.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Saquinavir.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Saquinavir.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Saquinavir.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Saquinavir.
NitrazepamThe serum concentration of Saquinavir can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Saquinavir.
NitrendipineThe serum concentration of Saquinavir can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Saquinavir can be increased when it is combined with Nizatidine.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Saquinavir.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Saquinavir.
NorethisteroneThe serum concentration of Saquinavir can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Saquinavir.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Saquinavir.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Saquinavir.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Saquinavir.
OctreotideOctreotide may increase the QTc-prolonging activities of Saquinavir.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Saquinavir.
OlanzapineThe serum concentration of Saquinavir can be increased when it is combined with Olanzapine.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Saquinavir.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Saquinavir.
OlaparibThe metabolism of Saquinavir can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Saquinavir.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Saquinavir.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Saquinavir.
OmeprazoleThe serum concentration of Saquinavir can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Saquinavir.
OndansetronOndansetron may increase the QTc-prolonging activities of Saquinavir.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Saquinavir.
OsimertinibThe serum concentration of Saquinavir can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Saquinavir.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Saquinavir.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Saquinavir.
OxycodoneThe risk or severity of adverse effects can be increased when Saquinavir is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Saquinavir.
OxytocinOxytocin may increase the QTc-prolonging activities of Saquinavir.
P-NitrophenolThe serum concentration of Saquinavir can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Saquinavir.
PaclitaxelThe serum concentration of Saquinavir can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Saquinavir can be increased when it is combined with Palbociclib.
PaliperidoneSaquinavir may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Saquinavir can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Saquinavir.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Saquinavir.
PanobinostatThe metabolism of Saquinavir can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Saquinavir can be increased when it is combined with Pantoprazole.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Saquinavir.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Saquinavir.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Saquinavir.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Saquinavir.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Saquinavir.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Saquinavir.
ParoxetineParoxetine may increase the QTc-prolonging activities of Saquinavir.
PasireotidePasireotide may increase the QTc-prolonging activities of Saquinavir.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Saquinavir.
PazopanibPazopanib may increase the QTc-prolonging activities of Saquinavir.
Peginterferon alfa-2bThe serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Saquinavir.
PentobarbitalThe metabolism of Saquinavir can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Saquinavir.
PerflutrenPerflutren may increase the QTc-prolonging activities of Saquinavir.
PergolideThe metabolism of Pergolide can be decreased when combined with Saquinavir.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Saquinavir.
PerindoprilThe serum concentration of Saquinavir can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Saquinavir.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Saquinavir.
PethidineThe risk or severity of adverse effects can be increased when Saquinavir is combined with Pethidine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Saquinavir.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Saquinavir.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Saquinavir.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Saquinavir.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Saquinavir.
PhenytoinThe metabolism of Saquinavir can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Saquinavir.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Saquinavir.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Saquinavir.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Saquinavir.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Saquinavir.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Saquinavir.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Saquinavir.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Saquinavir.
Platelet Activating FactorThe serum concentration of Saquinavir can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Saquinavir.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Saquinavir.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Saquinavir.
PonatinibThe serum concentration of Saquinavir can be increased when it is combined with Ponatinib.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Saquinavir.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Saquinavir.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Saquinavir.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Saquinavir.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Saquinavir resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Saquinavir.
PravastatinThe serum concentration of Saquinavir can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Saquinavir.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Saquinavir.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Saquinavir.
PrazosinThe serum concentration of Saquinavir can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Saquinavir.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Saquinavir.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Saquinavir.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Saquinavir.
PrimidoneThe metabolism of Saquinavir can be increased when combined with Primidone.
ProbenecidThe serum concentration of Saquinavir can be increased when it is combined with Probenecid.
ProcainamideSaquinavir may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Saquinavir.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Saquinavir.
ProguanilThe metabolism of Proguanil can be decreased when combined with Saquinavir.
PromazineSaquinavir may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Saquinavir can be decreased when combined with Promazine.
PromethazinePromethazine may increase the QTc-prolonging activities of Saquinavir.
PropafenoneSaquinavir may increase the arrhythmogenic activities of Propafenone.
PropafenoneThe serum concentration of Saquinavir can be increased when it is combined with Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Saquinavir.
PropofolThe metabolism of Propofol can be decreased when combined with Saquinavir.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Saquinavir.
PropranololThe serum concentration of Saquinavir can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Saquinavir.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Saquinavir.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Saquinavir.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Saquinavir.
QuazepamThe metabolism of Quazepam can be decreased when combined with Saquinavir.
QuercetinThe serum concentration of Saquinavir can be increased when it is combined with Quercetin.
QuetiapineSaquinavir may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Saquinavir.
QuinacrineThe serum concentration of Saquinavir can be increased when it is combined with Quinacrine.
QuinidineSaquinavir may increase the QTc-prolonging activities of Quinidine.
QuinidineThe serum concentration of Saquinavir can be increased when it is combined with Quinidine.
QuinineSaquinavir may increase the QTc-prolonging activities of Quinine.
QuinineThe serum concentration of Saquinavir can be increased when it is combined with Quinine.
RabeprazoleThe serum concentration of Saquinavir can be increased when it is combined with Rabeprazole.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Saquinavir.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Saquinavir.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Saquinavir.
RanitidineThe serum concentration of Saquinavir can be increased when it is combined with Ranitidine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Saquinavir.
RanolazineThe serum concentration of Saquinavir can be increased when it is combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Saquinavir.
ReboxetineThe serum concentration of Saquinavir can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Saquinavir.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Saquinavir.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Saquinavir.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Saquinavir.
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Saquinavir.
RifabutinThe metabolism of Saquinavir can be increased when combined with Rifabutin.
RifampicinThe risk or severity of adverse effects can be increased when Rifampicin is combined with Saquinavir.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Saquinavir.
RifapentineThe metabolism of Saquinavir can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Saquinavir.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Saquinavir.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Saquinavir.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Saquinavir.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Saquinavir.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Saquinavir.
RisperidoneRisperidone may increase the QTc-prolonging activities of Saquinavir.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Saquinavir.
RitonavirRitonavir may increase the QTc-prolonging activities of Saquinavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Saquinavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Saquinavir.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Saquinavir.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Saquinavir.
RolapitantThe serum concentration of Saquinavir can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Saquinavir.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Saquinavir.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Saquinavir.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Saquinavir.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Saquinavir.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Saquinavir.
Roxatidine acetateThe serum concentration of Saquinavir can be increased when it is combined with Roxatidine acetate.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Saquinavir.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Saquinavir.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Saquinavir.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Saquinavir.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Saquinavir.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Saquinavir.
ScopolamineThe serum concentration of Saquinavir can be increased when it is combined with Scopolamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Saquinavir.
SelegilineThe serum concentration of Saquinavir can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Saquinavir.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Saquinavir.
SertindoleThe metabolism of Sertindole can be decreased when combined with Saquinavir.
SertralineSertraline may increase the QTc-prolonging activities of Saquinavir.
SertralineThe metabolism of Sertraline can be decreased when combined with Saquinavir.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Saquinavir.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Saquinavir.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Saquinavir.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Saquinavir.
SildenafilThe metabolism of Saquinavir can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Saquinavir.
SiltuximabThe serum concentration of Saquinavir can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Saquinavir can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Saquinavir.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Saquinavir.
SirolimusThe serum concentration of Saquinavir can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Saquinavir.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Saquinavir.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Saquinavir.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Saquinavir.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Saquinavir.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Saquinavir.
SorafenibSorafenib may increase the QTc-prolonging activities of Saquinavir.
SotalolSaquinavir may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Saquinavir.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Saquinavir.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Saquinavir.
SpironolactoneThe serum concentration of Saquinavir can be increased when it is combined with Spironolactone.
St. John's WortThe metabolism of Saquinavir can be increased when combined with St. John's Wort.
StaurosporineThe serum concentration of Saquinavir can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Saquinavir can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Saquinavir can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Saquinavir.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Saquinavir.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Saquinavir.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Saquinavir.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Saquinavir.
SulfinpyrazoneThe serum concentration of Saquinavir can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleSaquinavir may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Saquinavir can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Saquinavir.
SumatriptanThe serum concentration of Saquinavir can be increased when it is combined with Sumatriptan.
SunitinibSunitinib may increase the QTc-prolonging activities of Saquinavir.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Saquinavir.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Saquinavir.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Saquinavir.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Saquinavir.
TacrineThe serum concentration of Saquinavir can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Saquinavir.
TacrolimusThe serum concentration of Saquinavir can be decreased when it is combined with Tacrolimus.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Saquinavir.
TAK-390MRThe serum concentration of Saquinavir can be increased when it is combined with TAK-390MR.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Saquinavir.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Saquinavir.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Saquinavir.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Saquinavir.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Saquinavir.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Saquinavir.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Saquinavir.
Taurocholic AcidThe serum concentration of Saquinavir can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Saquinavir.
TelaprevirThe metabolism of Saquinavir can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Saquinavir.
TelavancinSaquinavir may increase the QTc-prolonging activities of Telavancin.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Saquinavir.
TelmisartanThe serum concentration of Saquinavir can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Saquinavir.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Saquinavir.
TemsirolimusThe serum concentration of Saquinavir can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Saquinavir.
TerazosinThe serum concentration of Saquinavir can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Saquinavir.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Saquinavir.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Saquinavir.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Saquinavir.
TesmilifeneThe serum concentration of Saquinavir can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Saquinavir.
TestosteroneThe serum concentration of Saquinavir can be increased when it is combined with Testosterone.
TetrabenazineSaquinavir may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Saquinavir.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Saquinavir.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Saquinavir.
ThioridazineThe metabolism of Saquinavir can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Saquinavir.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Saquinavir.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Saquinavir.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Saquinavir.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Saquinavir resulting in a loss in efficacy.
TicagrelorThe serum concentration of Saquinavir can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Saquinavir can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Saquinavir.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Saquinavir.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Saquinavir.
TipranavirThe serum concentration of Saquinavir can be decreased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Saquinavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Saquinavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Saquinavir.
TocilizumabThe serum concentration of Saquinavir can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Saquinavir.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Saquinavir.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Saquinavir.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Saquinavir.
TolterodineTolterodine may increase the QTc-prolonging activities of Saquinavir.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Saquinavir.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Saquinavir.
ToremifeneThe risk or severity of adverse effects can be increased when Saquinavir is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Saquinavir.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Saquinavir.
TranylcypromineThe metabolism of Saquinavir can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Saquinavir.
TrazodoneSaquinavir may increase the QTc-prolonging activities of Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Saquinavir.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Saquinavir.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Saquinavir.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Saquinavir.
TrifluoperazineThe serum concentration of Saquinavir can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Saquinavir can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Saquinavir.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Saquinavir.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Saquinavir.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Saquinavir.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Saquinavir.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Saquinavir.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Saquinavir.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Saquinavir.
TroleandomycinThe serum concentration of Saquinavir can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Saquinavir.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Saquinavir.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Saquinavir.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Saquinavir.
VandetanibSaquinavir may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Saquinavir.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Saquinavir.
VardenafilVardenafil may increase the QTc-prolonging activities of Saquinavir.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Saquinavir.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Saquinavir.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Saquinavir.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Saquinavir.
VerapamilThe metabolism of Saquinavir can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Saquinavir.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Saquinavir.
VilanterolVilanterol may increase the QTc-prolonging activities of Saquinavir.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Saquinavir.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Saquinavir.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Saquinavir.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Saquinavir.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Saquinavir.
VincristineThe serum concentration of Saquinavir can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Saquinavir.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Saquinavir.
VinorelbineThe serum concentration of Saquinavir can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Saquinavir.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Saquinavir.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Saquinavir.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Saquinavir.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Saquinavir.
VorinostatVorinostat may increase the QTc-prolonging activities of Saquinavir.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Saquinavir.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Saquinavir.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Saquinavir.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Saquinavir.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Saquinavir.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Saquinavir.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Saquinavir.
ZileutonThe metabolism of Zileuton can be decreased when combined with Saquinavir.
ZimelidineThe serum concentration of Saquinavir can be increased when it is combined with Zimelidine.
ZiprasidoneSaquinavir may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Saquinavir can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Saquinavir.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Saquinavir.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Saquinavir.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Saquinavir.
ZuclopenthixolSaquinavir may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take after a full meal.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
  2. Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694 ]
  3. Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP: PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63. doi: 10.1002/jmv.21329. [PubMed:19040279 ]
  4. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW: HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26. [PubMed:20660676 ]
  5. Alcaro S, Artese A, Ceccherini-Silberstein F, Ortuso F, Perno CF, Sing T, Svicher V: Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance. J Chem Inf Model. 2009 Jul;49(7):1751-61. doi: 10.1021/ci900012k. [PubMed:19537723 ]
  6. Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K: A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antivir Ther. 1996 Aug;1(3):129-40. [PubMed:11322246 ]
  7. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH: Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75. [PubMed:9297727 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, Back DJ: Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos. 2001 Mar;29(3):299-303. [PubMed:11181499 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, Back DJ: Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos. 2001 Mar;29(3):299-303. [PubMed:11181499 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301 ]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409 ]
  5. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001 Apr;59(4):806-13. [PubMed:11259625 ]
  6. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  7. Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52. [PubMed:10583025 ]
  8. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM: Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar;28(3):329-34. [PubMed:10681378 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8. [PubMed:15007102 ]
  2. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, Khoo SH: Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS. 2005 Dec 2;19(18):2097-102. [PubMed:16284458 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Williams GC, Liu A, Knipp G, Sinko PJ: Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62. [PubMed:12384350 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Williams GC, Liu A, Knipp G, Sinko PJ: Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62. [PubMed:12384350 ]
  2. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH: Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002 Nov 22;16(17):2295-301. [PubMed:12441801 ]
  3. Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, Borst P: Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44. Epub 2003 Apr 17. [PubMed:12702717 ]
  4. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:40